Skip to main content
. 2021 Mar 15;12(10):2886–2892. doi: 10.7150/jca.47566

Figure 2.

Figure 2

Expression of CD163 and pCR status predict outcome of TNBC. Patients with low level of CD163 demonstrated longer RFS and OS than those with high level (P<0.05). Patients who achieved pCR had a better RFS and OS than those with non-pCR (P<0.05). A. RFS between patients with low and high level of CD163; B. RFS between patients with pCR and Non-pCR. C. OS between patients with low and high level of CD163; B. OS between patients with pCR and Non-pCR. TNBC: triple negative breast cancer; RFS: recurrence-free survival; OS: overall survival.